Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 2
2015 1
2017 1
2018 1
2020 1
2021 2
2022 3
2023 2
2025 3
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.
Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M, Brockow K, Siebenhaar F, Triggiani M, Arock M, Romantowski J, Górska A, Schwartz LB, Metcalfe DD. Valent P, et al. Int J Mol Sci. 2020 Nov 27;21(23):9030. doi: 10.3390/ijms21239030. Int J Mol Sci. 2020. PMID: 33261124 Free PMC article. Review.
When, in addition, the symptoms are recurrent, involve more than one organ system, and are responsive to therapy with MC-stabilizing or mediator-targeting drugs, the consensus criteria for the diagnosis of MCA syndrome (MCAS) are met. ...Most severe MCA event …
When, in addition, the symptoms are recurrent, involve more than one organ system, and are responsive to therapy with MC-stabilizi …
AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.
Aziz Q, Harris LA, Goodman BP, Simrén M, Shin A. Aziz Q, et al. Clin Gastroenterol Hepatol. 2025 Jul;23(8):1291-1302. doi: 10.1016/j.cgh.2025.02.015. Epub 2025 May 19. Clin Gastroenterol Hepatol. 2025. PMID: 40387691 Review.
BEST PRACTICE ADVICE 2: Testing for POTS/MCAS should be targeted to patients presenting with clinical manifestations of POTS/MCAS, but universal testing for POTS/MCAS in all patients with hEDS/HSDs is not supported by the current evidence. ...In addition to g …
BEST PRACTICE ADVICE 2: Testing for POTS/MCAS should be targeted to patients presenting with clinical manifestations of POTS/MCAS …
Mast Cell Activation Syndrome.
Frieri M. Frieri M. Clin Rev Allergy Immunol. 2018 Jun;54(3):353-365. doi: 10.1007/s12016-015-8487-6. Clin Rev Allergy Immunol. 2018. PMID: 25944644 Review.
Earlier criteria for MCAS diagnosis included episodic symptoms with mast cell mediators affecting two or more organ systems with urticaria, angioedema, flushing, nausea, vomiting, diarrhea, abdominal cramping, hypotensive syncope, tachycardia, wheezing, conjunctival inject …
Earlier criteria for MCAS diagnosis included episodic symptoms with mast cell mediators affecting two or more organ systems with urti …
A Case of Complex Regional Pain Syndrome With Hypermobile Ehlers-Danlos Syndrome and Mast Cell Activation Syndrome: The Role of Unconventional Therapies.
Shabbir Z, Mazdeyasnan L, McLain M. Shabbir Z, et al. Cureus. 2025 Jul 14;17(7):e87898. doi: 10.7759/cureus.87898. eCollection 2025 Jul. Cureus. 2025. PMID: 40809669 Free PMC article.
Montelukast, cromolyn sodium, and GI supplementation represent potential therapeutic interventions for managing patients with CRPS linked to MCAS. These treatments offer a novel approach by targeting mast cell-mediated inflammation. This case emphasizes the need for …
Montelukast, cromolyn sodium, and GI supplementation represent potential therapeutic interventions for managing patients with CRPS linked to …
[Meaningful intervention for postcovid].
de Klerk-van der Wiel I, Olde Loohuis AGM, Wessel CH. de Klerk-van der Wiel I, et al. Ned Tijdschr Geneeskd. 2025 Nov 3;169:D8523. Ned Tijdschr Geneeskd. 2025. PMID: 41258915 Dutch.
Interventions in the biological domain are aimed at 'treatable traits' such as pain, sleep problems, POTS and MCAS-type symptoms, as well as comorbidities. Comorbidities may require specialized care, and rehabilitative care may be necessary to stabilize the illness …
Interventions in the biological domain are aimed at 'treatable traits' such as pain, sleep problems, POTS and MCAS-type symptoms, as …
Mast cell activation syndromes: definition and classification.
Valent P. Valent P. Allergy. 2013 Apr;68(4):417-24. doi: 10.1111/all.12126. Epub 2013 Feb 15. Allergy. 2013. PMID: 23409940 Review.
When symptoms are recurrent, are accompanied by an increase in mast cell-derived mediators in biological fluids, and are responsive to treatment with mast cell-stabilizing or mediator-targeting drugs, the diagnosis of mast cell activation syndrome (MCAS) is a …
When symptoms are recurrent, are accompanied by an increase in mast cell-derived mediators in biological fluids, and are responsive to tr …
Mast cell activation syndrome: a review.
Frieri M, Patel R, Celestin J. Frieri M, et al. Curr Allergy Asthma Rep. 2013 Feb;13(1):27-32. doi: 10.1007/s11882-012-0322-z. Curr Allergy Asthma Rep. 2013. PMID: 23179866 Review.
Mast cell activation syndrome (MCAS) is a condition with signs and symptoms involving the skin, gastrointestinal, cardiovascular, respiratory, and neurologic systems. ...Other criteria included a decrease in the frequency, severity, or resolution of symptoms with anti-medi …
Mast cell activation syndrome (MCAS) is a condition with signs and symptoms involving the skin, gastrointestinal, cardiovascular, res …
Management of Adult Patients with Gastrointestinal Symptoms from Food Hypersensitivity-Narrative Review.
Kanikowska A, Janisz S, Mańkowska-Wierzbicka D, Gabryel M, Dobrowolska A, Eder P. Kanikowska A, et al. J Clin Med. 2022 Dec 9;11(24):7326. doi: 10.3390/jcm11247326. J Clin Med. 2022. PMID: 36555942 Free PMC article. Review.
Mast cell activation syndrome (MCAS) derives from pathologic reaction of mast cells with increased tryptase serum level as a marker. Symptoms may occur in the digestive, respiratory, skin, neurologic and cardiovascular system. Treatment is based on histamine type 1, …
Mast cell activation syndrome (MCAS) derives from pathologic reaction of mast cells with increased tryptase serum level as a marker. …
Multi-phasic life-threatening anaphylaxis refractory to epinephrine managed by extracorporeal membrane oxygenation (ECMO): A case report.
Grafeneder J, Ettl F, Warenits AM, Buchtele N, Lobmeyr E, Staudinger T, Schwameis M, Sperr WR, Gelbenegger G, Schoergenhofer C, Jilma B. Grafeneder J, et al. Front Allergy. 2022 Jul 29;3:934436. doi: 10.3389/falgy.2022.934436. eCollection 2022. Front Allergy. 2022. PMID: 35966228 Free PMC article.
We present a case of a 52-year-old patient suffering from multi-phasic life-threatening anaphylaxis refractory to epinephrine treatment. Extracorporeal membrane oxygenation (ECMO) therapy was initiated as the ultima ratio to stabilize the patient hemodynamica …
We present a case of a 52-year-old patient suffering from multi-phasic life-threatening anaphylaxis refractory to epinephrine treatment …
Delivery of small molecule mast cell activators for West Nile Virus vaccination using acetalated dextran microparticles.
Hendy DA, Johnson-Weaver BT, Batty CJ, Bachelder EM, Abraham SN, Staats HF, Ainslie KM. Hendy DA, et al. Int J Pharm. 2023 Mar 5;634:122658. doi: 10.1016/j.ijpharm.2023.122658. Epub 2023 Jan 30. Int J Pharm. 2023. PMID: 36731641 Free PMC article.
Several mast cell activating (MCA) compounds have been reported such as M7 and Compound 48/80 (C48/80). While these MCAs have been proven to be efficacious vaccine adjuvants, their translatability is limited by batch-to-batch variability, challenging large-scale manufactur …
Several mast cell activating (MCA) compounds have been reported such as M7 and Compound 48/80 (C48/80). While these MCAs have been pr …
21 results